Haleon PLC Sponsored ADR (NYSE:HLN) Receives $12.33 Average Price Target from Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $12.3250.

Several analysts recently commented on HLN shares. Barclays cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th.

Hedge Funds Weigh In On Haleon

A number of hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company’s stock valued at $192,428,000 after acquiring an additional 3,372,155 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares during the last quarter. Sculptor Capital LP boosted its holdings in Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company’s stock worth $111,645,000 after purchasing an additional 1,962,770 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Haleon by 6.5% during the second quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock worth $81,479,000 after buying an additional 476,823 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.7%

Shares of NYSE HLN opened at $9.47 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon has a one year low of $8.71 and a one year high of $11.42. The business has a 50-day moving average price of $9.28 and a two-hundred day moving average price of $9.92. The firm has a market capitalization of $42.19 billion, a PE ratio of 24.29, a PEG ratio of 2.84 and a beta of 0.20.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.